Articles tagged with Brain Tumors
The Novo-TTF device demonstrated significant efficacy in reducing tumor volume and improving outcomes for patients with locally advanced breast cancer. The device's non-invasive technology disrupts cancer cell proliferation, offering a potential alternative to traditional chemotherapy.
Researchers found that increasing production of angiotensin-converting enzyme in macrophages enhances the immune system's ability to sense and respond to tumors. This discovery suggests a strategy for amplifying immune system function in humans, potentially enhancing cancer patients' ability to resist tumor growth.
Researchers at the University of Adelaide will study links between brain chemistry and fatal outcomes from brain tumors and strokes. They aim to find out why these conditions become deadly, with a focus on swelling caused by tumors and cancer cells entering the central nervous system.
Researchers used perfusion MRI to track changes in blood volume in patients with low-grade gliomas, finding that increased rCBV is an indicator of future malignant transformation. The study suggests that significant changes in rCBV represent an early warning sign of impending malignant transformation.
Researchers have shown that MRI can non-invasively characterize brain tumors and determine which are responsive to specific treatments based on their molecular properties. The study identified five distinct MRI features linked with particular gene expression patterns, including those associated with tumor proliferation and growth.
Researchers identify KIFBbeta as a potential new neuronal tumor suppressor gene that mediates apoptosis in neural crest-derived tumors. The study suggests that KIFBbeta provides a protective effect against the development of these tumors.
Researchers found that proteins BMP2, BMP4 and BMP7 inhibit medulloblastoma tumor growth while inducing malignant cells to develop into normal neurons, offering a potential new treatment for the cancer.
A new mouse model of neurofibromatosis 1 closely replicates the human condition, allowing for more extensive and accurate preclinical testing of potential therapies. The model has been used to test chemotherapy agents and experimental drugs, revealing promising results and shedding light on their effects.
Researchers at Massachusetts General Hospital have identified a new strategy for normalizing tumor blood supply by controlling nitric oxide levels. By selectively suppressing NO production in tumor cells while maintaining it in blood vessels, the study found improved appearance and function of the tumor's blood supply.
A study found that people with gliomatosis cerebri missing chromosome 1p and 19q respond better to temozolomide and live longer. The genetic signature was associated with a higher response rate and longer survival, making temozolomide a preferred treatment option.
A new study has found that a gene called STAT3 can behave differently depending on genetic nuances between individuals, playing a tumor suppressor role in some glioblastoma cases. The discovery has laid the foundation for personalized medicine approaches to treat this devastating brain cancer.
The Simons Foundation's $10 million grant will support preclinical studies of new therapies for gliomas, a type of brain cancer. The goal is to develop treatments that target cancer cells and abnormal signaling pathways while sparing nearby sensitive tissues.
Researchers discovered that astatine-211 can kill residual cancer cells without harming sensitive brain tissue, leading to longer survival rates among patients. The isotope's potency and short lifespan make it a promising treatment option for brain tumors.
Research reveals high-dose methotrexate significantly increases average survival rate to 4.5 years, outperforming radiation therapy with a one-year average survival rate.
A study published in the Journal of Neurosurgery found that simultaneous implantation of radioactive seeds and chemotherapy wafers following surgery improved patient survival rates for recurrent glioblastoma multiforme (GBM) patients. The median survival was 69 weeks, with nearly a quarter of patients surviving two years.
Researchers at Cardiff University have made promising progress in treating tuberous sclerosis, an inherited disease that causes tumours to grow in organs. After a year of Sirolimus treatment, kidney tumour diameters shrunk by 26% on average.
A new brain mapping technique has refined scientists' understanding of language organization within the human cortex, identifying new regions involved in speech production, reading, and naming. The technique allows for safer tumor removal and better outcomes for patients with language-related difficulties.
Researchers developed a three-drug cocktail targeting glioblastoma multiforme tumors, which showed significant benefits in killing cancer cells and sparing healthy brain tissue. The treatment is based on the first-ever documented molecular signature of GBM tumors and may be tested in patients within five years.
Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified cancer stem cells as a potential cause of brain tumors. The study aims to develop more accurate and specific cancer diagnoses using these stem cells.
A clinical study at Henry Ford Hospital found that Avastin significantly extended the survival of patients with glioblastoma multiforme, with over half living without disease progression for six months. The use of Avastin also showed no new adverse effects.
Researchers found that blocking blood vessel growth with an antiangiogenic agent can reduce inflammation and improve antitumor efficacy of oncolytic virus therapy. This approach may increase survival rates for patients with aggressive brain tumors.
Bioengineers at Yale have created a new method of drug delivery that effectively targets and treats brain tumors by adding a water-soluble polymer to the anti-cancer drug. This approach has the potential to increase treatment distances, potentially preventing recurrence and improving treatment outcomes.
Researchers at Thomas Jefferson University found that stereotactic radiation is an effective alternative to surgery for benign brain tumors called non-acoustic schwannomas. The study showed excellent local tumor control with minimal side effects, making it a promising treatment option.
A common human virus, Human cytomegalovirus (HCMV), has been found to be associated with the deadliest form of brain tumors, glioblastoma multiforme. Researchers at Duke University Medical Center have developed a vaccine targeting HCMV that could empower the body's immune system to fight infected tumor cells and destroy cancer.
A new study found that a combination of bevacizumab (Avastin) and chemotherapy may increase survival time for patients with glioblastoma multiforme, a deadly type of brain tumor. The treatment showed promising results in improving outcomes for patients who have already been diagnosed with the disease.
Researchers found that certain existing drugs can target and inhibit the growth of brain tumors by modifying key signaling molecules. The study suggests that these drugs may be repurposed for treatment of brain tumors.
Researchers found a new chemotherapy regimen of irinotecan and cisplatin to be effective in treating childhood brainstem gliomas, with all six children showing significant tumor reduction. While the disease eventually progressed in three children, this is a promising breakthrough for a previously difficult-to-treat cancer.
Researchers at Dana-Farber Cancer Institute have found that many brain tumors and solid tumors require simultaneous inhibition of multiple cell-growth switches to be effective. Combining three or more targeted drugs may provide a cure for these cancers, as individual drugs often yield disappointing results.
Researchers have developed a customized virus, Delta-24-RGD, that targets and eliminates brain tumor stem cells. In lab experiments and human brain cancer in mice, the virus shows promise in killing glioblastoma multiforme tumors, which are resistant to radiation and chemotherapy.
A Johns Hopkins study shows an experimental compound called cyclopamine successfully kills cancer stem cells that fuel tumor growth and help cancers evade drug and radiation therapy. The study provides evidence for a potential new therapy for glioblastoma, a deadly brain cancer.
A novel 3D cell culture model has been developed to study the selective uptake of nanoparticles in brain tumors. The model uses a combination of tumor aggregates and normal brain tissue slices, allowing researchers to investigate tumor cell invasion into brain tissue.
A team of researchers is using cutting-edge neuroimaging technology to identify predictors of adaptive functioning in adults who survived pediatric brain tumors. The study aims to develop interventions to lessen the severity of late effects of treatment and optimize adaptive functioning across the patient's lifespan.
A recent study published in The Lancet Oncology found that children with intracranial ependymoma can avoid the damaging effects of radiotherapy by receiving chemotherapy treatment instead. In a study of 89 children, 42% avoided radiotherapy and had better overall survival rates.
A new report found that children with brain tumors have lower grades in each subject, particularly in foreign language, with over 58% of female patients receiving below an eight. Despite this, most survivors completed the ninth grade at the usual age, suggesting a glimmer of hope for these students.
Researchers developed a new cancer treatment called Chlorotoxin:Cy5.5, which can illuminate tumor cells in the operating room, making it easier for surgeons to remove all cancerous cells without injuring surrounding healthy tissue. This technology has the potential to improve cancer therapy and save lives.
Patients with von Hippel-Lindau disease may experience sudden hearing loss due to endolymphatic sac tumors (ELSTs) associated with significant dysfunction of hearing and balance. Surgical intervention may be warranted for early diagnosis and treatment of ELSTs.
A genetic factor has been identified that predicts prognosis in brain tumor patients. The Notch2 gene is a key regulator of developmental processes and its loss positively predicts survival in subgroups of brain tumor cases. This finding offers new targets for molecular intervention to develop drugs against this severe human disease.
Researchers found vorinostat's anti-cancer activity in patients with recurrent glioblastoma multiforme, with a 15% patient success rate and improved median overall survival. The study aimed to explore the novel application of vorinostat in targeting brain cancer.
R. Edward Coleman received the award for his contributions to molecular imaging and nuclear medicine practice, particularly in advancing positron emission tomography (PET) for breast cancer, Alzheimer's, and brain tumors. His research has had a significant impact on medicine, and he is recognized as one of the best doctors in America.
A recent study published by researchers at Duke University Medical Center and The University of Texas M. D. Anderson Cancer Center has found that chemotherapy may actually enhance the effectiveness of cancer vaccines used to treat brain tumors. The process by which immune cells regenerate after being wiped out by chemotherapy makes the...
Using metabolic imaging, UCLA researchers found that FLT-PET is a powerful predictor of treatment response and outcome in brain tumor patients. The study showed that FLT-PET imaging was predictive of patients' overall survival, with those who responded to drug treatment living three times as long as those who did not.
A study of 149 patients with low-grade gliomas found that temozolomide reduced tumor size in 53% and stabilized it in 37%, while increasing it in 10%. Genetic testing revealed that missing the 1p/19q gene was associated with better treatment outcomes.
Researchers at UIC College of Pharmacy have developed a hydrogel-based delivery system to control chemotherapy drug release for glioblastoma multiforme and other solid tumors, reducing side effects. The innovative approach aims to improve survival rates for brain tumor patients.
A new drug that targets the body's immune cells has shown promise in treating malignant brain tumors by re-engaging the cancer-damaged immune system. The researchers found that the drug stops 'bad' T cells from damaging the immune system and gives 'good' T cells a type of bulletproof jacket, enabling them to better fight off brain tumors.
Patients with rare brain tumors may have a genetic predisposition to develop the condition. Radiation exposure increases the risk of developing these tumors in families where multiple members are exposed.
Researchers are developing gene therapies that can target and kill cancer cells, while also exploring the use of viruses and other natural systems to design new cancer treatments. Studies have shown promising results in animal models, including a novel gene therapy approach that eradicates aggressive prostate cancer.
A clinical trial at UCSF Brain Tumor Research Center has shown promising results using the vitespen vaccine to stimulate the immune system to attack tumor cells. The vaccine, made from a patient's own tumor, induced a tumor-specific immune response in all 12 study patients.
Researchers discovered a protein made by microglia that helps accelerate tumor growth, and are looking for others. The findings have implications for both genetic and sporadic brain tumors.
A study found that survivors of acute lymphoblastic leukemia have a significantly increased risk of secondary cancers developing over time. The cumulative incidence of secondary neoplasms increases from 4.17% at 15 years to 10.85% at 30 years, with the majority being low-grade tumors.
A study by St. Jude Children's Research Hospital found that adults who survived childhood acute lymphoblastic leukemia (ALL) are at a higher risk of developing secondary neoplasms during adulthood. Most of these late-onset tumors are low-grade and curable, but some can cause significant health issues.
Boston College biologists identify KetoCal as an effective alternative therapy for malignant brain cancer, slowing tumor growth and enhancing health in mice. The study found that KetoCal decreased tumor growth by 35-65% and improved survival rates compared to standard diets.
Researchers found that dual therapy with Avastin and chemotherapy agent irinotecan halted tumor growth up to twice as long as comparative therapies, offering a significant advance in treatment for aggressive gliomas. The study's findings may lead to new options for patients with the poorest possible prognosis.
Researchers found that Olig2, a transcription factor, enables tumor growth in brain cancer by repressing cell-replication brake p21. Knocking out Olig2 function nearly eliminated tumor formation in mouse models.
A study by St. Jude researchers found that brain tumors arise from cancer stem cells living in microscopic protective niches formed by blood vessels, disrupting these niches may block tumor growth. The team showed that targeting blood vessel cells could eliminate CSCs and prevent tumor reappearance following treatment.
Researchers found that blood vessels associated with brain tumors create a microenvironment that sustains cancer stem cells. Disrupting this microenvironment with antiangiogenic drugs reduces CSCs and arrests tumor growth.
AZD2171, a new angiogenesis inhibitor, has shown significant promise in treating glioblastomas by reducing tumor size and alleviating debilitating brain swelling. The treatment also appears to normalize blood vessels, creating a window of opportunity for other therapies to be more effective.
Researchers at St. Jude Children's Research Hospital and City of Hope National Medical Center developed genetically modified stem cells that seek out and destroy even tiny tumors in the nervous system, using a chemotherapy drug that selectively targets cancer cells.
Researchers at Cedars-Sinai Medical Center identified genes that make brain cancer-causing stem cells resistant to chemotherapy and other treatments. The study found that these cells can regenerate and become even more aggressive after treatment, highlighting a potential target for new therapies.
Researchers at Barrow and Arizona State University will develop new hydrogels to stimulate spinal cord growth and treat brain tumors. The studies aim to improve treatment options for patients with malignant brain tumors and spinal cord injuries, building on the center's reputation as a top neuroscience hub.
A population-based study of 13,613 brain tumor cases in Sweden found that people with four or more siblings were twice as likely to develop a brain tumor. Children under 15 with three or more younger siblings had a two to fourfold increase in brain tumors compared to those with no siblings.